Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.3: prohibited at all times. Non-Specified. [1]
S4.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Clinical research
Landogrozumab, indexed as LY2495655, is a myostatin antibody. A randomized study of 201 adults aged at least 75 with prior falls and low muscle performance found a modest increase in appendicular lean mass. Functional findings varied across tests, with a less stringent pre-specified significance level for physical-performance outcomes. Injection-site reactions were more common with active treatment. [2] [3]
- Abstract-level appraisal; gains in lean mass are not the same as demonstrated prevention of falls or disability.
A separate trial population
A 400-person hip-replacement trial did not meet its primary threshold for improvement in appendicular lean mass, despite some later body-composition changes. Other exploratory functional measures did not show meaningful group differences. [3]
- Patients undergoing surgery are not interchangeable with older fallers or healthy athletes.
What remains uncertain
- The draft’s pancreatic-cancer safety discussion was not reappraised in this pass and is omitted. No current authorization or retail-product safety claim is made.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial ↗Accessed 2026-11-10 · Primary-study abstract on author institution record
Primary-study abstract
- Landogrozumab LY2495655 hip arthroplasty trial ↗Accessed 2026-11-10 · Primary-study abstract and metadata
Abstract and bibliographic record
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.